Protagonist Therapeutics Inc. (PTGX)
$148.80
$2.72
(1.86%)
As on 03-Sep-2026 16:00EDT
Market cap
$9,339 Mln
Revenue (TTM)
$282 Mln
P/E Ratio
140.1
P/B Ratio
11.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
148.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$1
-
Face value
--
-
Shares outstanding
64,708,285
10 Years Aggregate
CFO
$-498.42 Mln
EBITDA
$-614.20 Mln
Net Profit
$-607.32 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
| 70.4 | 8.9 | 59.6 | 152.8 | 96.7 | 24.6 | 28.5 |
|
BSE Sensex
| -10.1 | -2.5 | 2.0 | -5.0 | 5.2 | 5.7 | 10.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
| 126.3 | 67.6 | 110.2 | -68.1 | 69.6 | 186.0 | 4.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
148.8 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
| 86.5 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 271.1 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 74.0 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.1 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.8 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 371.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 542.6 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 593.4 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 355.2 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Protagonist Therapeutics (PTGX)
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and... older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Read more
-
CEO, President, Secretary & Director
Dr. Dinesh V. Patel Ph.D.
-
CEO, President, Secretary & Director
Dr. Dinesh V. Patel Ph.D.
-
Headquarters
Newark, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Protagonist Therapeutics (PTGX)
What is the current share price of Protagonist Therapeutics Inc (PTGX) Today?
The share price of Protagonist Therapeutics Inc (PTGX) is $148.80 (NASDAQ) as of 03-Sep-2026 16:00 EDT. Protagonist Therapeutics Inc (PTGX) has given a return of 96.74% in the last 3 years.
What is the current PB & PE ratio of Protagonist Therapeutics Inc (PTGX)?
The P/E ratio of Protagonist Therapeutics Inc (PTGX) is 140.13 times as on 28-Aug-2026.
The P/B ratio of Protagonist Therapeutics Inc (PTGX) is 11.49 times as on 28-Aug-2026, a 122 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-42.66 |
9.03 |
2024 |
9.31 |
3.80 |
2023 |
-17.95 |
4.21 |
2022 |
-4.35 |
2.49 |
2021 |
-13.12 |
5.49 |
What is the 52 Week High and Low of Protagonist Therapeutics Inc (PTGX)?
The 52-week high and low of Protagonist Therapeutics Inc (PTGX) are Rs 160.81 and Rs 54.50 as of 04-Sep-2026.
What is the market cap of Protagonist Therapeutics Inc (PTGX)?
Protagonist Therapeutics Inc (PTGX) has a market capitalisation of $ 9,339 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Protagonist Therapeutics Inc (PTGX)?
Before investing in Protagonist Therapeutics Inc (PTGX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.